Brief: Neuphoria Announces Initiation Of Strategic Review
11/11/2025 12:55
Nov 11 (Reuters) - Neuphoria Therapeutics Inc NEUP.O: NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUE NEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LP NEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIA Source text: ID:nGNX7PmsfF Further company coverage: NEUP.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Neuphoria Therapeutics
See all newsBrief: Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing
NASDAQ RESUMED AT 03:25 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:20 PM
Brief: Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell
Brief: Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium